CleneCLNN
About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Employees: 85
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
85% more capital invested
Capital invested by funds: $2.53M [Q2] → $4.66M (+$2.14M) [Q3]
74% more call options, than puts
Call options by funds: $282K | Put options by funds: $162K
10.17% more ownership
Funds ownership: 5.52% [Q2] → 15.69% (+10.17%) [Q3]
46% less funds holding
Funds holding: 37 [Q2] → 20 (-17) [Q3]
71% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 24
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 13
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
D. Boral Capital Jason Kolbert 26% 1-year accuracy 39 / 152 met price target | 360%upside $23 | Buy Maintained | 19 Dec 2024 |
Benchmark Bruce Jackson 48% 1-year accuracy 26 / 54 met price target | 1,580%upside $84 | Buy Maintained | 22 Nov 2024 |
Canaccord Genuity Sumant Kulkarni 25% 1-year accuracy 8 / 32 met price target | 1,560%upside $83 | Buy Maintained | 14 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 81 / 386 met price target | 520%upside $31 | Buy Reiterated | 14 Nov 2024 |
EF Hutton Jason Kolbert 26% 1-year accuracy 39 / 152 met price target | 360%upside $23 | Buy Maintained | 24 Oct 2024 |